Financial reports
10-K
2023 FY
Annual report
22 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
ARS
2022 FY
Annual report to shareholders
18 Apr 23
10-K
2022 FY
Annual report
23 Feb 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
10-K
2021 FY
Annual report
24 Feb 22
Current reports
8-K
Departure of Directors or Certain Officers
15 Apr 24
8-K
Termination of a Material Definitive Agreement
22 Mar 24
8-K
Amendment No. 1 to the Open Market Sale Agreementsm
23 Feb 24
8-K
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress
22 Feb 24
8-K
Regulation FD Disclosure
1 Feb 24
8-K
Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones
4 Jan 24
8-K
Departure of Directors or Certain Officers
6 Dec 23
8-K
Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
9 Nov 23
8-K
Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting
2 Nov 23
8-K
Intellia Therapeutics Announces FDA Clearance of
18 Oct 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
26 Feb 24
424B5
Prospectus supplement for primary offering
23 Feb 24
S-8
Registration of securities for employees
22 Feb 24
S-3ASR
Automatic shelf registration
24 Nov 23
S-8
Registration of securities for employees
23 Feb 23
424B5
Prospectus supplement for primary offering
1 Dec 22
424B5
Prospectus supplement for primary offering
4 Mar 22
S-8
Registration of securities for employees
24 Feb 22
424B5
Prospectus supplement for primary offering
1 Jul 21
424B5
Prospectus supplement for primary offering
28 Jun 21
Proxies
PRE 14A
Preliminary proxy
16 Apr 24
DEFA14A
Additional proxy soliciting materials
5 Jun 23
DEFA14A
Additional proxy soliciting materials
1 May 23
DEF 14A
Definitive proxy
1 May 23
PRE 14A
Preliminary proxy
18 Apr 23
DEFA14A
Additional proxy soliciting materials
2 May 22
DEF 14A
Definitive proxy
2 May 22
DEFA14A
Additional proxy soliciting materials
28 Apr 21
DEF 14A
Definitive proxy
28 Apr 21
DEFA14A
Additional proxy soliciting materials
24 Apr 20
Other
CT ORDER
Confidential treatment order
1 Sep 20
EFFECT
Notice of effectiveness
13 Sep 19
CORRESP
Correspondence with SEC
10 Sep 19
CORRESP
Correspondence with SEC
30 Aug 19
UPLOAD
Letter from SEC
29 Aug 19
EFFECT
Notice of effectiveness
7 Jun 19
CORRESP
Correspondence with SEC
4 Jun 19
CT ORDER
Confidential treatment order
9 May 19
CT ORDER
Confidential treatment order
11 Mar 19
UPLOAD
Letter from SEC
11 Mar 19
Ownership
4
Laura Sepp-Lorenzino
5 Mar 24
4
JAMES BASTA
5 Mar 24
4
Derek Hicks
5 Mar 24
4
Eliana Clark
5 Mar 24
4
JOHN M LEONARD
5 Mar 24
4
David Lebwohl
5 Mar 24
4
Glenn Goddard
5 Mar 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
ARK Investment Management LLC
29 Jan 24
SC 13G/A
STATE STREET CORP
24 Jan 24